WuXi AppTec Co., Ltd. (603259.SS) has a MoatMap StockRank of 91/100 based on Quality (79/100), Value (47/100), and Momentum (53/100) factor scores. The current signal is STRONG BUY. WuXi AppTec is a world-class CDMO with exceptional quality metrics. However, it is a primary casualty of the US Biosecure Act and escalating US-China geopolitical tensions. The threat of being shut out of the US market creates an asymmetric downside risk that overrides its operational quality.
WuXi AppTec is a global provider of R&D and manufacturing services (CRDMO) enabling the pharmaceutical, biotech, and medical device industries. The company's competitive moat lies in its fully integrated, end-to-end platform that spans small molecule discovery, development, manufacturing, and cell/gene therapies. As a dominant global market leader, it benefits from high switching costs and a massive, diversified international client base.
| Price | $14.39 |
| Market Cap | $44.8B |
| P/E (TTM) | 13.92 |
| P/E (Forward) | 13.51 |
| Price/Book | 3.41 |
| Return on Equity | 25.7% |
| Return on Invested Capital | 28.9% |
| Debt/Equity | 9.88 |
| Gross Margin | 50.7% |
| Operating Margin | 40.6% |
| Revenue Growth | 28.8% |
| Dividend Yield | 2.0% |
| Free Cash Flow | $196M |
WuXi AppTec Co., Ltd. operates in the Diagnostics & Research industry, part of the Healthcare sector (China).